

## Case Study | Ensysce Biosciences

# Securing the best price for an out-licensed asset

Biotech Ensysce, whose mission is to stem the prescription drug abuse crisis, seeks out-licensing or partnering opportunities around the world for its proprietary abuse and overdose resistant prodrug technologies.

**However, the company lacked a comprehensive overview of the pipeline landscape to identify potential opportunities and needed reliable data regarding the type of deals previously executed by potential partners.**

The company turned to Cortellis Deals Intelligence™ because, when used in combination with Cortellis Competitive Intelligence™, it offers all the data the company needs — deals, drug, company and patent information — in one platform.

### Cortellis Deals Intelligence has helped Ensysce:



make successful deals faster, without sacrificing due diligence,



negotiate a higher price than what it originally thought it could obtain and



have greater confidence in its deal-making decisions,



identify potential out-licensing partners based on their experience or gaps in the Ensysce portfolio.



save time and effort gathering data from multiple sources,

**"By using Cortellis Deals Intelligence in conjunction with Cortellis Competitive Intelligence, we have an even stronger competitive edge by combining insights on deals with extensive pipeline, company and patent information."**

**Richard Wright,  
Chief Business Officer, Ensysce Biosciences Inc.**

For more information on how Cortellis Deals Intelligence can help you negotiate your best possible deal, visit our website at:

**[clarivate.com/dealsintelligence](https://clarivate.com/dealsintelligence)**

© 2022 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.